All five claims of US patent 7,622,115 – covering methods for treating cancer with Roche’s Avastin (bevacizumab) oncology treatment – have been declared as invalid by the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO), following inter partes review proceedings initiated by Hospira.
All five claims of US patent 7,622,115 – covering methods for treating cancer with Roche’s Avastin (bevacizumab) oncology treatment – have been declared as invalid by the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO), following inter partes review proceedings initiated by Hospira.
The ‘115 patent claims methods for treating cancer comprising administering bevacizumab and assessing the patient for gastrointestinal perforation. It discloses...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
